WO2010136952A2 - Self-microemulsifying mitotane composition - Google Patents
Self-microemulsifying mitotane composition Download PDFInfo
- Publication number
- WO2010136952A2 WO2010136952A2 PCT/IB2010/052292 IB2010052292W WO2010136952A2 WO 2010136952 A2 WO2010136952 A2 WO 2010136952A2 IB 2010052292 W IB2010052292 W IB 2010052292W WO 2010136952 A2 WO2010136952 A2 WO 2010136952A2
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- mitotane
- propylene glycol
- oily formulation
- composition
- formulation
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
- A61K9/1075—Microemulsions or submicron emulsions; Preconcentrates or solids thereof; Micelles, e.g. made of phospholipids or block copolymers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4841—Filling excipients; Inactive ingredients
- A61K9/4858—Organic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
Definitions
- the invention relates to a self-microemulsifying drug delivery system ("SMEDDS”) of mitotane, with enhanced bioavailability.
- SMEDDS self-microemulsifying drug delivery system
- Mitotane (o,p'-DDD or I .i -dichlorodiphenyldichloroethane) is an adrenolytic agent which is particularly useful in the treatment of non-resectable and metastasized adrenocortical carcinoma.
- mitotane has poor solubility in gastro-intestinal tract and low bioavailability when administered as a conventional tablet in humans. Attempts were made to solve this problem.
- a first self-microemulsifying drug delivery system (“SMEDDS”) of mitotane was developed, comprising mitotane dissolved in a matrix composed of an equal mixture of capryol®90, Tween®20 and Cremophor EL® (33:33:33) (Attivi et al, "Development of a self-microemulsifying drug delivery system of mitotane (o,p'-DDD) using a mixture design methodology", Chimiometrie 2006, Ajana Imane, 2006, Master “Sciences de Ia vie et de Ia sante", Nancy- Universite).
- this system could not load more than 250mg of mitotane in I OOOmg of matrix, which is not enough to produce capsules of an acceptable size and would therefore seriously entail patients' compliance with the treatment. Optimization of this system was thus needed.
- the invention provides a delivery system which incorporates high mitotane loads without forming precipitates in the presence of water.
- the invention provides a mitotane oily formulation which comprises mitotane in a matrix comprising a. propylene glycol monocaprylate; from 10 to 30% of the total weight of the mitotane oily formulation (w/w) b. propylene glycol dicaprate; from 20 to 60% of the total weight of the mitotane oily formulation (w/w) c. polyoxyethylenesorbitanne monooleate. from 10 to 30% of the total weight of the mitotane oily formulation (w/w)
- this matrix can accommodate a drug loading of at least 33%, preferably at least 39%.
- This oily formulation is capable of forming a microemulsion in situ with the biological fluids of the body.
- the invention further provides a pharmaceutical composition comprising such mitotane oily formulation.
- This pharmaceutical composition which is preferably in the form of a capsule, is useful in treating cancer, in particular adrenocortical carcinoma.
- Another subject of the invention is a method for preparing a mitotane oily formulation suitable for forming a self-microemulsifying drug delivery system, which method comprises dissolving mitotane in a mixture of propylene glycol monocaprylate, propylene glycol dicaprate and polyoxyethylenesorbitanne monooleate in proportions as recited above.
- 'matrix' refers to a mixture of excipients.
- 'mitotane oily formulation' refers to a matrix in which mitotane has been incorporated.
- Drug loading corresponds to the weight of mitotane with respect to the total weight of the matrix. (Equation (1 ))
- SMEDDS self-microemulsifying drug delivery systems
- SMEDDS self-microemulsifying drug delivery systems
- isotropic mixtures of lipid, surfactant, cosurfactant, and drug that rapidly form a microemulsion when mixed with water Such systems are described in greater details in Grove and M ⁇ llertz, "Liquid Self-Microemulsifying Drug Delivery Systems", Oral Lipid-Based Formulations - Enhancing the Bioavailability of Poorly Water-Soluble Drugs, edited by David J. Hauss, lnforma Healthcare, 2007, Chapter 5.
- Self-emulsifying formulations are readily dispersed in the gastrointestinal tract, where the motility of the stomach and small intestine provides the agitation necessary for emulsification.
- the lipophilic phase comprises propylene glycol dicaprate, polyoxyethylenesorbitanne monooleate that acts as a surfactant, and propylene glycol monocaprylate that acts as a cosurfactant.
- Propylene glycol monocaprylate is available under the name Capryol®90 (Gattefosse).
- Propylene glycol dicaprate is available under the name Captex®100 (Abitec corp.).
- Polyoxyethylenesorbitanne monooleate is available under the name Tween®80 (Sigma) or is also known as polysorbate 80 (or “PS 80" in the examples below).
- the oily formulation has a drug loading of at least 33%, preferably between 33% and 67%, and more preferably between 37% and 54%.
- the mitotane oily formulation comprises a. from 10 to 30 % w/w of propylene glycol monocaprylate, preferably from 15 to 20%, more preferably from 15 to 17% w/w; b. from 20 to 60 % w/w of propylene glycol dicaprate, preferably from 35 to 50%, more preferably from 38 to 42% w/w; c. from 10 to 30 % w/w of polyoxyethylenesorbitanne monooleate, preferably from 15 to 20%, more preferably from 15 to 17% w/w.
- the mitotane oily formulation of the invention makes it possible to load at least 33%, preferably at least 39% of mitotane (i.e. 400mg mitotane for I OOOmg of the matrix made of the mixture of lipid, surfactant and cosurfactant).
- mitotane i.e. 400mg mitotane for I OOOmg of the matrix made of the mixture of lipid, surfactant and cosurfactant.
- propylene glycol monocaprylate, propylene glycol dicaprate and polyoxyethylenesorbitanne monooleate represent a total amount of between 65 and 75 % w/w in the mitotane oily formulation.
- the oily formulation of the invention advantageously forms a microemulsion comprising droplets having a size of less than 200nm, when mixed with water or HCI.
- the mitotane oily formulation can be packaged in any pharmaceutical composition for oral administration.
- Suitable oral compositions that comprise the oily formulation of the invention are generally capsules, including hard gelatin capsules or soft gelatin capsules.
- soft gelatin capsules are made with a gelatin shell, optionally in association with plasticizers such as glycerine and/or sorbitol. Encapsulation is achieved by techniques known in the art.
- the composition may be a liquid dispersed directly into the patient's mouth.
- the pharmaceutical composition may then comprise water or an aqueous phase, in which the oily mitotane formulation is dispersed in the form of a microemulsion.
- the mitotane oily formulation may be packaged into a solid dosage form, in a state readily converted to a microemulsion in vivo, which thereby enhances the dissolution of the drug.
- composition of mitotane oily formulation for therapeutic use advantageously contains between 100 and 400 mg mitotane, preferably between 100 and 300mg.
- a particular example of a composition according to the invention is a soft gelatin capsule encapsulating an oily formulation comprising from 33% to 66% of mitotane drug load and a matrix comprising : a. propylene glycol monocaprylate: from 15 to 17% of the total weight of the mitotane oily formulation (w/w) b. propylene glycol dicaprate: from 38 to 42% of the total weight of the mitotane oily formulation (w/w) c.
- the mitotane oily formulation of the invention which is suitable for forming a self- microemulsifying drug delivery system may be prepared by dissolving mitotane in a mixture of propylene glycol monocaprylate, propylene glycol dicaprate and polyoxyethylenesorbitanne monooleate in proportions as recited above.
- Drug loading of at least 33%, preferably at least 39%, can be achieved by immediate dispersion upon dilution into a homogenous solution.
- the dissolution step may also be carried out by mixing for at least 5 minutes with heating to not more than 40-50 0 C.
- the SMEDDS system of the invention enhances the dissolution of mitotane, and its bioavailability. Further food effect is reduced.
- Figure 2 is a graph that shows mitotane rate of absorption in fed conditions.
- Solubility was determined by incremental loading of mitotane. A typical increment solubility study is summarized below:
- Stability was determined by placing the systems in a refrigerator (5°C) or left at room temperature. At a minimum of 24 hours, solutions were visually evaluated. Any precipitate was noted.
- Microemulsions comprising droplets of a size inferior to 200nm appear as clear solutions. Any hazy appearance or precipitate is noted.
- Water tolerance study further allows to determine whether the system will self- emulsify in the presence of gastro-intestinal fluid in vivo, for instance.
- Table 1 shows formulations with the best drug loading, which were selected for further studies.
- Formulations numbered 1 to 4 were eventually set aside, as high mitotane loads could not be incorporated.
- Table 2 shows the characteristics of the two selected formulations. Table 2: Selected formulations
- Formulations #054 and 057 according to the invention were tested in dogs, in a screening study vs. Lysodren® (mitotane tablets commercially available from HRA pharma). Three Beagle dogs/group were used per formulation. One group is administered with one Lysodren tablet comprising 500mg of mitotane, one group is administered with two hard gelatin capsules comprising 280mg mitotane each in formulation #054 and one group is administered with two hard gelatin capsules comprising 280mg mitotane each in formulation #057. The formulations were compared in fed and fasted conditions, including administrations on fed dogs and then fasted dogs in cross over with a wash out period of 3 weeks. 10 samples were collected at: 0, 1 , 2, 3, 4, 5, 6, 8, 10 and 12 hours post administration.
- Relative bioavailability data vs Lysodren® are as follows: Lysodren® : 100% Batch # 054 : 150 % Batch # 057 : 317% See Figure 1.
- This example provides a protocol for manufacturing mitotane SMEDDS soft gelatin capsules having the following composition:
- step 4 Charge step 4 into step 3 under continuous mixing. 6. Rinse step 5 container with the reserved purified water and charge into step
- Encapsulation and processing 1. Carry out the encapsulation
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Dispersion Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Medicinal Preparation (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
Description
Claims
Priority Applications (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2012512500A JP5572699B2 (en) | 2009-05-25 | 2010-05-24 | Self-microemulsifying mitotane composition |
ES10726290.9T ES2472424T3 (en) | 2009-05-25 | 2010-05-24 | Composition of self-emulsifying mitotane |
US13/322,222 US8486445B2 (en) | 2009-05-25 | 2010-05-24 | Self-microemulsifying mitotane composition |
BRPI1010563A BRPI1010563A2 (en) | 2009-05-25 | 2010-05-24 | "Mitotane oil formulation, method for preparation thereof and pharmaceutical composition" |
EP10726290.9A EP2435022B1 (en) | 2009-05-25 | 2010-05-24 | Self-microemulsifying mitotane composition |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP09160999A EP2255786A1 (en) | 2009-05-25 | 2009-05-25 | Self-microemulsifying mitotane composition |
EP09160999.0 | 2009-05-25 |
Publications (2)
Publication Number | Publication Date |
---|---|
WO2010136952A2 true WO2010136952A2 (en) | 2010-12-02 |
WO2010136952A3 WO2010136952A3 (en) | 2012-01-19 |
Family
ID=41056723
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/IB2010/052292 WO2010136952A2 (en) | 2009-05-25 | 2010-05-24 | Self-microemulsifying mitotane composition |
Country Status (6)
Country | Link |
---|---|
US (1) | US8486445B2 (en) |
EP (2) | EP2255786A1 (en) |
JP (1) | JP5572699B2 (en) |
BR (1) | BRPI1010563A2 (en) |
ES (1) | ES2472424T3 (en) |
WO (1) | WO2010136952A2 (en) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2012071043A1 (en) * | 2010-11-24 | 2012-05-31 | Pharmaceutics International, Inc. | Self micro-emulsifying drug delivery system with increased bioavailability |
Families Citing this family (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN102846544B (en) * | 2011-08-29 | 2014-01-15 | 华北制药集团新药研究开发有限责任公司 | Self-microemulsion composition of insoluble medicine |
FR3102356B1 (en) | 2019-10-28 | 2021-09-17 | Mohamed Skiba | PHARMACEUTICAL COMPOSITION INCLUDING MITOTANE FOR ORAL ADMINISTRATION FOR THE TREATMENT OF CORTICOSURRENAL CARCINOMA AND CUSHING SYNDROME |
Family Cites Families (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4146648A (en) * | 1977-07-14 | 1979-03-27 | Bristol-Myers Company | Chemotherapeutic composition |
JP2001515491A (en) * | 1997-03-12 | 2001-09-18 | アボツト・ラボラトリーズ | Lipophilic binary system for administration of lipophilic compounds |
US6294192B1 (en) * | 1999-02-26 | 2001-09-25 | Lipocine, Inc. | Triglyceride-free compositions and methods for improved delivery of hydrophobic therapeutic agents |
JP5028885B2 (en) * | 2006-07-04 | 2012-09-19 | 大正製薬株式会社 | Ubidecalenone-containing self-emulsifying composition |
-
2009
- 2009-05-25 EP EP09160999A patent/EP2255786A1/en not_active Withdrawn
-
2010
- 2010-05-24 JP JP2012512500A patent/JP5572699B2/en not_active Expired - Fee Related
- 2010-05-24 WO PCT/IB2010/052292 patent/WO2010136952A2/en active Application Filing
- 2010-05-24 ES ES10726290.9T patent/ES2472424T3/en active Active
- 2010-05-24 EP EP10726290.9A patent/EP2435022B1/en not_active Not-in-force
- 2010-05-24 US US13/322,222 patent/US8486445B2/en not_active Expired - Fee Related
- 2010-05-24 BR BRPI1010563A patent/BRPI1010563A2/en not_active Application Discontinuation
Non-Patent Citations (1)
Title |
---|
ATTIVI ET AL.: "Development of a self-microemulsifying drug delivery system of mitotane (o,p'-DDD) using a mixture design methodology", CHIMIOMETRIE, 2006 |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2012071043A1 (en) * | 2010-11-24 | 2012-05-31 | Pharmaceutics International, Inc. | Self micro-emulsifying drug delivery system with increased bioavailability |
US9770509B2 (en) | 2010-11-24 | 2017-09-26 | Pharmaceutics International, Inc. | Self micro-emulsifying drug delivery system with increased bioavailability |
Also Published As
Publication number | Publication date |
---|---|
ES2472424T3 (en) | 2014-07-01 |
EP2255786A1 (en) | 2010-12-01 |
WO2010136952A3 (en) | 2012-01-19 |
JP5572699B2 (en) | 2014-08-13 |
US20130017258A1 (en) | 2013-01-17 |
US8486445B2 (en) | 2013-07-16 |
EP2435022B1 (en) | 2014-04-02 |
JP2012528141A (en) | 2012-11-12 |
BRPI1010563A2 (en) | 2016-03-15 |
EP2435022A2 (en) | 2012-04-04 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
KR100441167B1 (en) | Composition of microemulsion preconcentrate | |
US20140056974A1 (en) | Spontaneously Dispersible N-Benzoyl Staurosporine Compositions | |
JP2022549729A (en) | Pharmaceutical composition containing abiraterone acetate, and method for production and use thereof | |
WO2004017958A1 (en) | Soft capsule preparation | |
JP6282645B2 (en) | Racecadotril lipid composition | |
TW201808306A (en) | Composite formulation of dutasteride and tadalafil comprising glycerol fatty acid ester derivative or propylene glycol fatty acid ester derivative and oral capsule formulation comprising the same | |
CN1903228A (en) | Prepn. of self-emulsion of glossy ganoderma spore oil, and its prepn. method | |
JP2016512828A (en) | Racecadotril lipid composition | |
EP2779997B1 (en) | Liquid-filled hard gel capsule pharmaceutical formulations | |
CN106999558A (en) | Base undecylate composition of (17 β) 3 oxygen androstane-14 alkene 17 and its production and use | |
EP2435022B1 (en) | Self-microemulsifying mitotane composition | |
CN102470121B (en) | Pharmaceutical compositions comprising dronedarone | |
TWI599368B (en) | Capsule for oral administration comprising pharmaceutical composition alisporivir | |
SG195015A1 (en) | Pharmaceutical composition comprising fexofenadine | |
JP2017518980A (en) | Anti-modification immediate release capsule formulation containing tapentadol | |
TW202128150A (en) | 3'-[(2Z)-[1-(3,4-dimethylphenyl)-1,5-dihydro-3-methyl-5-oxo-4H-pyrazol-4-ylidene]hydrazino]-2'-hydroxy-[1,1'-biphenyl]-3-carboxylic acid and its salts formulation | |
TWI280129B (en) | Pharmaceutical composition for oral administration of a pyrazole-3-carboxamide derivative | |
KR102329411B1 (en) | Pharmaceutical Composition Comprising R-Thioctic Acid, Oil and Dispersing Agent | |
CZ300424B6 (en) | Pharmaceutical composition for peroral administration | |
CN103784405B (en) | A preparation for improving oral bioavailability of risedronate sodium and a preparing method thereof | |
EP4228612A1 (en) | Oral cannabinoid formulation comprising tocopheryl phosphates and long chain triglycerides or long chain fatty acids | |
EP4228613A1 (en) | Oral cannabinoid formulation comprising medium chain triglycerides and tocopheryl phosphates | |
JP2017500355A (en) | Racecadotril composition | |
KR20220095506A (en) | Carvedilol loaded solid oral compositions using self-nanoemulsifying drug delivery system and methods for their preparation | |
RU2642244C2 (en) | Oral pharmaceutical compositions of testosterone esters and method for testosterone shortage treatment with their use |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 10726290 Country of ref document: EP Kind code of ref document: A2 |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2012512500 Country of ref document: JP |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2010726290 Country of ref document: EP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 13322222 Country of ref document: US |
|
REG | Reference to national code |
Ref country code: BR Ref legal event code: B01A Ref document number: PI1010563 Country of ref document: BR |
|
ENP | Entry into the national phase |
Ref document number: PI1010563 Country of ref document: BR Kind code of ref document: A2 Effective date: 20111124 |